SK Pharm and Hanmi Pharm Will Bring Epilepsy Treatment to China

Two Korean biopharmas, SK Biopharmaceuticals and Hanmi Pharm, announced a strategic partnership to bring an epilepsy drug to China and Korea. SK Biopharm developed the drug – the seizure control and muscle relaxant treatment diazepam, which is delivered by a nasal spray. Hanmi’s China subsidiary will be in charge of obtaining SFDA approval for the drug and marketing it in China and Korea. More details.... Share this with colleagues: var switchTo5x=true; stLight.options({publisher:'d7871f5b-67bc-4d30-b66f-1465d0b97213'});